{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:37:38Z","timestamp":1791873458000,"version":"4.3.4"},"reference-count":97,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer research and therapy. These range from the identification of the first specific chromosomal abnormality associated with cancer to the development of imatinib as a specific, targeted therapy for the disease. The successful development of imatinib as a therapeutic agent for CML can be attributed directly to decades of scientific discoveries. These discoveries determined that the BCR-ABL tyrosine kinase is the critical pathogenetic event in CML and an ideal target for therapy. This was confirmed in clinical trials of imatinib, with imatinib significantly improving the long-term survival of patients with CML. Continuing in this tradition of scientific discoveries leading to improved therapies, the understanding of resistance to imatinib has rapidly led to strategies to circumvent resistance. Continued studies of hematologic malignancies will allow this paradigm of targeting molecular pathogenetic events to be applied to many additional hematologic cancers.<\/jats:p>","DOI":"10.1182\/blood-2008-07-077958","type":"journal-article","created":{"date-parts":[[2008,12,8]],"date-time":"2008-12-08T20:43:25Z","timestamp":1228769005000},"page":"4808-4817","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":553,"title":["Translation of the Philadelphia chromosome into therapy for CML"],"prefix":"10.1182","volume":"112","author":[{"given":"Brian J.","family":"Druker","sequence":"first","affiliation":[{"name":"Howard Hughes Medical Institute, Oregon Health & Science University Cancer Institute, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111716310362000_B1","first-page":"413","article-title":"Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood.","volume":"64","author":"Bennett","year":"1845","journal-title":"Edinb Med Surg J"},{"key":"2019111716310362000_B2","first-page":"151","article-title":"Weisses Blut.","volume":"36","author":"Virchow","year":"1845","journal-title":"Frorieps Notizen"},{"key":"2019111716310362000_B3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2141.2000.02137.x","article-title":"The story of chronic myeloid leukaemia.","volume":"10","author":"Geary","year":"2000","journal-title":"Br J Haematol"},{"key":"2019111716310362000_B4","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis.","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"2019111716310362000_B5","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nature07016","article-title":"PML targeting eradicates quiescent leukaemia-initiating cells.","volume":"453","author":"Ito","year":"2008","journal-title":"Nature"},{"key":"2019111716310362000_B6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/shem.2002.33612","article-title":"Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide.","volume":"39","author":"O'Dwyer","year":"2002","journal-title":"Semin Hematol"},{"key":"2019111716310362000_B7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"2019111716310362000_B8","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia.","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"2019111716310362000_B9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining.","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"2019111716310362000_B10","first-page":"2213","article-title":"Lymphosarcoma: virus-induced thymic-independent disease in mice.","volume":"30","author":"Abelson","year":"1970","journal-title":"Cancer Res"},{"key":"2019111716310362000_B11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0092-8674(80)90554-1","article-title":"Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA.","volume":"22","author":"Goff","year":"1980","journal-title":"Cell"},{"key":"2019111716310362000_B12","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1073\/pnas.80.12.3623","article-title":"Nucleotide sequence of Abelson murine leukemia virus genome: structural similarity of its transforming gene product to other onc gene products with tyrosine-specific kinase activity.","volume":"80","author":"Reddy","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111716310362000_B13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0092-8674(84)90228-9","article-title":"The mouse c-abl locus: molecular cloning and characterization.","volume":"36","author":"Wang","year":"1984","journal-title":"Cell"},{"key":"2019111716310362000_B14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","article-title":"A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia.","volume":"300","author":"de Klein","year":"1982","journal-title":"Nature"},{"key":"2019111716310362000_B15","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia.","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"2019111716310362000_B16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22.","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"2019111716310362000_B17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1126\/science.6587568","article-title":"Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells.","volume":"225","author":"Collins","year":"1984","journal-title":"Science"},{"key":"2019111716310362000_B18","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1073\/pnas.81.18.5648","article-title":"An 8-kilobase abl RNA transcript in chronic myelogenous leukemia.","volume":"81","author":"Gale","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111716310362000_B19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"key":"2019111716310362000_B20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene.","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"2019111716310362000_B21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1128\/MCB.5.1.204","article-title":"Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties.","volume":"5","author":"Davis","year":"1985","journal-title":"Mol Cell Biol"},{"key":"2019111716310362000_B22","doi-asserted-by":"crossref","first-page":"9768","DOI":"10.1073\/pnas.83.24.9768","article-title":"Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome.","volume":"83","author":"Mes-Masson","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111716310362000_B23","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1073\/pnas.78.3.1552","article-title":"Evidence that the Abelson virus protein functions in vivo as a protein kinase that phosphorylates tyrosine.","volume":"78","author":"Sefton","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111716310362000_B24","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/283826a0","article-title":"Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine.","volume":"283","author":"Witte","year":"1980","journal-title":"Nature"},{"key":"2019111716310362000_B25","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","article-title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.","volume":"37","author":"Konopka","year":"1984","journal-title":"Cell"},{"key":"2019111716310362000_B26","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"2019111716310362000_B27","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome.","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"2019111716310362000_B28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/344251a0","article-title":"Acute leukaemia in bcr\/abl transgenic mice.","volume":"344","author":"Heisterkamp","year":"1990","journal-title":"Nature"},{"key":"2019111716310362000_B29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","article-title":"Biology of chronic myelogenous leukemia\u2013signaling pathways of initiation and transformation.","volume":"18","author":"Melo","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111716310362000_B30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1126\/science.3263702","article-title":"Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors.","volume":"242","author":"Yaish","year":"1988","journal-title":"Science"},{"key":"2019111716310362000_B31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1128\/JVI.64.1.61-68.1990","article-title":"Regulation of pp60c-src and its interaction with polyomavirus middle T antigen in insect cells.","volume":"64","author":"Piwnica-Worms","year":"1990","journal-title":"J Virol"},{"key":"2019111716310362000_B32","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJM198911163212007","article-title":"Oncogenes, growth factors, and signal transduction.","volume":"321","author":"Druker","year":"1989","journal-title":"N Engl J Med"},{"key":"2019111716310362000_B33","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1073\/pnas.92.7.2558","article-title":"Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.","volume":"92","author":"Buchdunger","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111716310362000_B34","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/0960-894X(96)00197-7","article-title":"Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors.","volume":"6","author":"Zimmermann","year":"1996","journal-title":"Bioorg Med Chem Lett"},{"key":"2019111716310362000_B35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ardp.19963290707","article-title":"Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC).","volume":"329","author":"Zimmermann","year":"1996","journal-title":"Arch Pharm"},{"key":"2019111716310362000_B36","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"2019111716310362000_B37","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells.","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"2019111716310362000_B38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.","volume":"105","author":"Druker","year":"2000","journal-title":"J Clin Invest"},{"key":"2019111716310362000_B39","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins.","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"key":"2019111716310362000_B40","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"2019111716310362000_B41","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia.","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"2019111716310362000_B42","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","article-title":"The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.","volume":"90","author":"Deininger","year":"1997","journal-title":"Blood"},{"key":"2019111716310362000_B43","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1006\/bcmd.1997.0155","article-title":"Inhibition of the ABL kinase activity blocks the proliferation of BCR\/ABL+ leukemic cells and induces apoptosis.","volume":"23","author":"Gambacorti-Passerini","year":"1997","journal-title":"Blood Cells Mol Dis"},{"key":"2019111716310362000_B44","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"2019111716310362000_B45","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"2019111716310362000_B46","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.","volume":"346","author":"Kantarjian","year":"2002","journal-title":"New Engl J Med"},{"key":"2019111716310362000_B47","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study.","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"2019111716310362000_B48","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"2019111716310362000_B49","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"2019111716310362000_B50","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111716310362000_B51","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"2019111716310362000_B52","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"2019111716310362000_B53","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","article-title":"Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.","volume":"22","author":"Shah","year":"2003","journal-title":"Oncogene"},{"key":"2019111716310362000_B54","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111716310362000_B55","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111716310362000_B56","doi-asserted-by":"crossref","first-page":"22925","DOI":"10.1016\/S0021-9258(17)31596-X","article-title":"Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.","volume":"269","author":"Oda","year":"1994","journal-title":"J Biol Chem"},{"key":"2019111716310362000_B57","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood.V84.9.2912.2912","article-title":"Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.","volume":"84","author":"Nichols","year":"1994","journal-title":"Blood"},{"key":"2019111716310362000_B58","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.V84.6.1731.1731","article-title":"Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.","volume":"84","author":"ten Hoeve","year":"1994","journal-title":"Blood"},{"key":"2019111716310362000_B59","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"2019111716310362000_B60","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res"},{"key":"2019111716310362000_B61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1389557043487321","article-title":"Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.","volume":"4","author":"Cowan-Jacob","year":"2004","journal-title":"Mini Rev Med Chem"},{"key":"2019111716310362000_B62","doi-asserted-by":"crossref","first-page":"32214","DOI":"10.1074\/jbc.M111525200","article-title":"Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.","volume":"277","author":"Corbin","year":"2002","journal-title":"J Biol Chem"},{"key":"2019111716310362000_B63","first-page":"470a","article-title":"Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571 [abstract].","volume":"96","author":"Corbin","year":"2000","journal-title":"Blood"},{"key":"2019111716310362000_B64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"2019111716310362000_B65","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"2019111716310362000_B66","first-page":"3127","article-title":"The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells.","volume":"60","author":"Dorsey","year":"2000","journal-title":"Cancer Res"},{"key":"2019111716310362000_B67","first-page":"7149","article-title":"Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).","volume":"62","author":"La Ros\u00e9e","year":"2002","journal-title":"Cancer Res"},{"key":"2019111716310362000_B68","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays.","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"2019111716310362000_B69","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor.","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"2019111716310362000_B70","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"key":"2019111716310362000_B71","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111716310362000_B72","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"2019111716310362000_B73","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111716310362000_B74","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"2019111716310362000_B75","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111716310362000_B76","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"key":"2019111716310362000_B77","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"2019111716310362000_B78","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"2019111716310362000_B79","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"2019111716310362000_B80","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"key":"2019111716310362000_B81","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"2019111716310362000_B82","doi-asserted-by":"crossref","first-page":"2180a","DOI":"10.1182\/blood.V108.11.2180.2180","article-title":"Orally active inhibitors of the imatinib resistant Bcr-Abl mutant T315I [abstract].","volume":"108","author":"Shakespeare","year":"2006","journal-title":"Blood"},{"key":"2019111716310362000_B83","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1073\/pnas.0800587105","article-title":"SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.","volume":"105","author":"O'Hare","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111716310362000_B84","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2004-08-3373","article-title":"Punish the parent not the progeny.","volume":"105","author":"Elrick","year":"2005","journal-title":"Blood"},{"key":"2019111716310362000_B85","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.gde.2005.11.002","article-title":"Targeted CML therapy: controlling drug resistance, seeking cure.","volume":"16","author":"O'Hare","year":"2006","journal-title":"Curr Opin Genet Dev"},{"key":"2019111716310362000_B86","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2002.20.6.1692","article-title":"Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.","volume":"20","author":"Heinrich","year":"2002","journal-title":"J Clin Oncol"},{"key":"2019111716310362000_B87","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2165\/00003495-200767050-00012","article-title":"Imatinib: a review of its use in the management of gastrointestinal stromal tumours.","volume":"67","author":"Siddiqui","year":"2007","journal-title":"Drugs"},{"key":"2019111716310362000_B88","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"2019111716310362000_B89","doi-asserted-by":"crossref","first-page":"4a","DOI":"10.1182\/blood.V110.11.4.4","article-title":"Improved early event free survival (EFS) in children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with intensive imatinib in combination with high dose chemotherapy: children's oncology group (COG) study AALL0031 [abstract].","volume":"110","author":"Schultz","year":"2007","journal-title":"Blood"},{"key":"2019111716310362000_B90","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"key":"2019111716310362000_B91","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"2019111716310362000_B92","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood-2002-01-0165","article-title":"Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene.","volume":"100","author":"Magnusson","year":"2002","journal-title":"Blood"},{"key":"2019111716310362000_B93","first-page":"173b","article-title":"STI571 inhibits the kinase activity of wild type and juxtamembrane c-kit mutants but not the exon 17 D816V mutation associated with mastocytosis [abstract].","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"2019111716310362000_B94","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors: kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"2019111716310362000_B95","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate.","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"2019111716310362000_B96","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111716310362000_B97","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1073\/pnas.0932698100","article-title":"Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.","volume":"100","author":"Griffin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/13\/4808\/1288184\/zh802508004808.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/13\/4808\/1288184\/zh802508004808.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T04:48:28Z","timestamp":1632718108000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/112\/13\/4808\/24918\/Translation-of-the-Philadelphia-chromosome-into"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,15]]},"references-count":97,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2008,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-07-077958","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,15]]}}}